Ferring to acquire microbiome company Rebiotix

Women's health and gastroenterology company Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland) will acquire microbiome company Rebiotix Inc. (Roseville, Minn.). The companies declined to disclose financial terms.

Ferring said the acquisition complements its own microbiome research. The Swiss company will gain RBX2660, an intestinal microbiota suspension in Phase III testing to prevent recurrent Clostridium difficile infection (CDI). The candidate has breakthrough therapy and Orphan Drug designations in the U.S. for the indication. The companies declined to comment on when Phase III data are expected...